Markus Müschen, MD, PhD, has been appointed the inaugural Director of the Center of Molecular and Cellular Oncology at Yale Cancer Center and Smilow Cancer Hospital. “As an innovative and highly productive physician-scientist, Dr. Müschen’s leadership experience and mentorship will be a tremendous asset for Yale Cancer Center, as we continue to expand our efforts in cancer research and hematologic malignancies,” said Charles Fuchs, MD, MPH, Director of Yale Cancer Center and Physician-in-Chief at Smilow Cancer Hospital.
Markus Müschen, MD, PhD
Charles Fuchs, MD, MPH
Dr. Müschen joins Yale from City of Hope Comprehensive Cancer Center, where he currently is Associate Director of Basic Science and Professor and Chair of the Department of Systems Biology. He is a Howard Hughes Medical Institute Faculty Scholar; a National Cancer Institute Outstanding Investigator Award (R35) recipient; formerly a scholar of the Leukemia & Lymphoma Society; a senior investigator of the Wellcome Trust at the University of Cambridge, United Kingdom; and the Sir Alexander Haddow Professor of the Institute for Cancer Research in London.
Establishing Novel Approaches
Over the past 10 years, Dr. Müschen has developed a multidisciplinary research program to study oncogenic signaling and clonal evolution in B-cell malignancies. In addition, his research has been addressing fundamental questions in immunobiology and immunotherapy and the development of new advances in chimeric antigen receptor T-cell therapy.
Previously, Dr. Müschen trained in hematology-oncology at the University of Cologne Medical Center in Germany, where he also completed postdoctoral studies in immunology at the University’s Institute for Genetics. He graduated from Heinrich-Heine-Universität in Düsseldorf, Germany. From 2009 to 2016, Dr. Müschen was a tenured Professor of Laboratory Medicine, Pathology, and Medicine at the University of California, San Francisco (UCSF) and served as Program Leader of the Hematological Malignancies Program of the UCSF Helen Diller Comprehensive Cancer Center.
